Metabolic Impact of Prospective Controlled Mediterranean Type Diets on Prostate Cancer
Recruiting · NCT05590624 · Interventional (participants receive a specific treatment) · Lead sponsor: Case Comprehensive Cancer Center
View the official record on ClinicalTrials.gov →Interventions studied
Low-Fat Med-t-DietLower-Carbohydrate Med-t-Diet
What this trial is about
The purpose of this study is to examine the impact of Mediterranean-type diets on the metabolism of men with localized prostate cancer. The optimal diet for men with a suspected diagnosis of Prostate Cancer (PCa) is currently unknown. More specifically, the suggested benefits of low carbohydrate and low fat diets in PCa are not determined.
Who can take part
Age range
18 Years and older
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Males ≥18 years old
- High suspicion of prostate cancer (PCa) per urologist's clinical evaluation
- BMI \>18.5
- No prior PCa diagnosis or hormonal therapy (-ies)
- Ability to read, write, speak, and understand English
- Ability to provide informed consent
- Candidate for and elects active surveillance (AS) if diagnostic biopsy is positive
- Willingness to consume provided dietary interventions
- Adequate organ and marrow function: White blood cell count (WBC) ≥2,500/mcL, Absolute neutrophil count (ANC) ≥1,500/mcL, Platelets ≥100,000/mcL, Hemoglobin ≥9 g/dL (transfusions permitted), Total bilirubin ≤1.5 x the institutional upper limit of normal (ULN) (for subjects with Gilbert's disease ≤3.0 mg/dL), Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) ≤2.5 x institutional ULN, Creatinine clearance ≥51 ml/min as defined by Cockcroft-Gault equation
Exclusion criteria
- Currently consuming a Mediterranean, lower carbohydrate, ketogenic, vegan, vegetarian, high fiber diet (14g fiber \> per 1,000 Calories) and/or any supplements (including herbal), vitamins, minerals, that would interfere with diets being tested in the study as determined by dietitian and/or investigators.
- Previous intolerability to fiber-rich diets
- Colitis, Irritable Bowel Syndrome, or other gastrointestinal condition per clinician discretion
- Unwilling to undergo transperineal PCa biopsies
- Food allergies or other major dietary restrictions
- Receiving active medical treatment for Type I or Type II diabetes mellitus
- Prior antibiotic usage (i.e. within last 30 days) at time of consent
- Recent weight loss (both intentional and unintentional) as defined by 5%+ body weight in the last 30 days
- Undergone any type of weight loss surgery
- Any medical contraindications as determined by investigators
- High risk as defined by PSA≥20 and/or PI-RADS 5 lesion as per clinician evaluation
- History of diabetic ketoacidosis
- Gout
- Patients that are immunosuppressed (transplant history, on immunosuppression, etc.) as per clinician discretion
- Recent (within last 30 days) device implant/joint requiring antibiotics as per clinician determination
- Prior history of prostate biopsy infection
- Uncontrolled hypertension as defined by blood pressure greater than 140/80 (with or without medication)
- Gallbladder removed or plan to remove per clinician evaluation
- Other malignancies actively receiving systemic treatment as per clinician evaluation
Where it is running
1 location listed across 1 US state.
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation - Cleveland, Ohio, United States